Analysts Expect Avrobio Inc (NASDAQ:AVRO) Will Announce Earnings of -$0.76 Per Share

Share on StockTwits

Brokerages predict that Avrobio Inc (NASDAQ:AVRO) will report earnings per share of ($0.76) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Avrobio’s earnings. The highest EPS estimate is ($0.70) and the lowest is ($0.78). Avrobio reported earnings per share of ($2.98) in the same quarter last year, which would suggest a positive year-over-year growth rate of 74.5%. The firm is expected to announce its next quarterly earnings results on Thursday, August 8th.

According to Zacks, analysts expect that Avrobio will report full-year earnings of ($2.93) per share for the current financial year, with EPS estimates ranging from ($3.12) to ($2.54). For the next year, analysts forecast that the business will report earnings of ($3.07) per share, with EPS estimates ranging from ($3.45) to ($2.65). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Avrobio.

Avrobio (NASDAQ:AVRO) last released its earnings results on Monday, May 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.01).

Several analysts recently issued reports on AVRO shares. Cowen reiterated a “buy” rating on shares of Avrobio in a report on Monday. Mizuho assumed coverage on Avrobio in a research note on Wednesday, June 26th. They issued a “buy” rating and a $28.00 price objective on the stock. Janney Montgomery Scott assumed coverage on Amicus Therapeutics in a research note on Friday, April 5th. They issued a “buy” rating and a $13.91 price objective on the stock. HC Wainwright set a $25.00 price objective on Onconova Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 14th. Finally, Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $27.90.

AVRO traded up $0.47 on Friday, hitting $23.37. 17,861 shares of the company were exchanged, compared to its average volume of 211,280. Avrobio has a 12 month low of $11.85 and a 12 month high of $53.70. The company has a market cap of $462.66 million and a P/E ratio of -6.33. The company has a fifty day moving average price of $14.99.

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its stake in Avrobio by 60.6% in the fourth quarter. Bank of New York Mellon Corp now owns 25,937 shares of the company’s stock valued at $431,000 after buying an additional 9,782 shares during the period. Rhumbline Advisers bought a new position in shares of Avrobio during the first quarter worth approximately $296,000. Aisling Capital Management LP increased its stake in shares of Avrobio by 10.2% during the first quarter. Aisling Capital Management LP now owns 811,998 shares of the company’s stock worth $17,905,000 after purchasing an additional 75,000 shares during the period. Emerald Advisers LLC increased its stake in shares of Avrobio by 61.4% during the first quarter. Emerald Advisers LLC now owns 614,408 shares of the company’s stock worth $13,548,000 after purchasing an additional 233,772 shares during the period. Finally, BlackRock Inc. increased its stake in shares of Avrobio by 73.4% during the fourth quarter. BlackRock Inc. now owns 651,959 shares of the company’s stock worth $10,854,000 after purchasing an additional 276,018 shares during the period. Hedge funds and other institutional investors own 71.13% of the company’s stock.

Avrobio Company Profile

AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.

Featured Story: What is a resistance level?

Get a free copy of the Zacks research report on Avrobio (AVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avrobio (NASDAQ:AVRO)

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Deutsche Bank Lowers Deere & Company  Price Target to $155.00
Deutsche Bank Lowers Deere & Company Price Target to $155.00
OMV  Downgraded by Goldman Sachs Group to Neutral
OMV Downgraded by Goldman Sachs Group to Neutral
Royal Bank of Scotland Group  Lowered to Neutral at Macquarie
Royal Bank of Scotland Group Lowered to Neutral at Macquarie
Oxford Instruments  Downgraded to Hold at Zacks Investment Research
Oxford Instruments Downgraded to Hold at Zacks Investment Research
Aldeyra Therapeutics  Rating Lowered to Hold at Zacks Investment Research
Aldeyra Therapeutics Rating Lowered to Hold at Zacks Investment Research
Invictus Financial  vs. Zillow Group  Head-To-Head Review
Invictus Financial vs. Zillow Group Head-To-Head Review


 
© 2006-2019 Zolmax.